Sartorius Stedim Biotech (Sartorius Stedim Biotech) Debt-to-Equity : 1.40 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sartorius Stedim Biotech Debt-to-Equity?

Sartorius Stedim Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $86 Mil. Sartorius Stedim Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3,929 Mil. Sartorius Stedim Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $2,877 Mil. Sartorius Stedim Biotech's debt to equity for the quarter that ended in Dec. 2023 was 1.40.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sartorius Stedim Biotech's Debt-to-Equity or its related term are showing as below:

SDMHF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.12 Med: 0.19 Max: 1.4
Current: 1.4

During the past 13 years, the highest Debt-to-Equity Ratio of Sartorius Stedim Biotech was 1.40. The lowest was 0.12. And the median was 0.19.

SDMHF's Debt-to-Equity is ranked worse than
92.42% of 712 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs SDMHF: 1.40

Sartorius Stedim Biotech Debt-to-Equity Historical Data

The historical data trend for Sartorius Stedim Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Debt-to-Equity Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.41

0.38

0.46

1.40

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.46	0.54	0.53	1.46	1.40

Competitive Comparison of Sartorius Stedim Biotech's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sartorius Stedim Biotech's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Debt-to-Equity falls into.

Sartorius Stedim Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sartorius Stedim Biotech's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(86.26	+	3929.008)	/	2876.663
	=	1.40

Sartorius Stedim Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(86.26	+	3929.008)	/	2876.663
	=	1.40

Sartorius Stedim Biotech (OTCPK:SDMHF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sartorius Stedim Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech (Sartorius Stedim Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (OTCPK:SDMHF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SRTOY:USA DIM:Mexico DIMp:UK 0RG8:UK DIM:France 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.